74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vir Biotechnology Inc
Closed
SectorHealthcare
5.92 -8.5
Overview
Share price change
24h
Min
5.85
Max
6.47
Income | 109M -105M |
|---|---|
Sales | 8.9M 11M |
EPS | -0.76 |
Profit margin | -927.372 |
Employees | 408 |
EBITDA | 97M -118M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +417.8% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -385M 919M |
|---|---|
Previous open | 14.42 |
Previous close | 5.92 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Vir Biotechnology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vir Biotechnology Inc Forecast
Price Target
By TipRanks
417.8% upside
12 Months Forecast
Average 32 USD 417.8%
High 110 USD
Low 14 USD
Based on 9 Wall Street analysts offering 12 month price targets forVir Biotechnology Inc - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
